Evaluation of eLIFT for Non-invasive Assessment of Liver fibrosis and Cirrhosis in Patients with Chronic Hepatitis B Virus Infection

Abstract Recently, the easy Liver Fibrosis Test (eLIFT), a sum of points attributed to age, gender, gamma-glutamyl transpeptidase, aspartate transaminase, platelets, and prothrombin time, was developed for diagnosing advanced fibrosis and cirrhosis in chronic liver disease. We aimed to evaluate the...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Qiang Li, Chuan Lu, Weixia Li, Yuxian Huang, Liang Chen
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/2b5c10b831b94534b2acdeed63ecce70
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2b5c10b831b94534b2acdeed63ecce70
record_format	dspace
spelling	oai:doaj.org-article:2b5c10b831b94534b2acdeed63ecce702021-12-02T16:06:41ZEvaluation of eLIFT for Non-invasive Assessment of Liver fibrosis and Cirrhosis in Patients with Chronic Hepatitis B Virus Infection10.1038/s41598-017-05718-x2045-2322https://doaj.org/article/2b5c10b831b94534b2acdeed63ecce702017-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-05718-xhttps://doaj.org/toc/2045-2322Abstract Recently, the easy Liver Fibrosis Test (eLIFT), a sum of points attributed to age, gender, gamma-glutamyl transpeptidase, aspartate transaminase, platelets, and prothrombin time, was developed for diagnosing advanced fibrosis and cirrhosis in chronic liver disease. We aimed to evaluate the performance of eLIFT to predict liver fibrosis and cirrhosis in patients with chronic hepatitis B (CHB). Histologic and laboratory data of 747 CHB patients were analyzed. The performance of eLIFT for diagnosing liver fibrosis and cirrhosis was compared with that of aspartate transaminase to platelet ratio index (APRI) and fibrosis index based on the 4 factors (FIB-4). To predict advanced fibrosis, the AUROC of eLIFT was comparable with that of APRI (0.66 vs 0.71, p = 0.095) and FIB-4 (0.66 vs 0.67, p = 0.612). To predict severe fibrosis, the AUROC of eLIFT was lower than that of APRI (0.65 vs 0.83, p < 0.001) and FIB-4 (0.65 vs 0.82, p < 0.001). To predict cirrhosis, the AUROC of eLIFT was also lower than that of APRI (0.64 vs 0.85, p = 0.001) and FIB-4 (0.64 vs 0.76, p = 0.033). The eLIFT is not a good non-invasive test for the diagnosis of liver fibrosis and cirrhosis in CHB patients.Qiang LiChuan LuWeixia LiYuxian HuangLiang ChenNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-7 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Qiang Li Chuan Lu Weixia Li Yuxian Huang Liang Chen Evaluation of eLIFT for Non-invasive Assessment of Liver fibrosis and Cirrhosis in Patients with Chronic Hepatitis B Virus Infection
description	Abstract Recently, the easy Liver Fibrosis Test (eLIFT), a sum of points attributed to age, gender, gamma-glutamyl transpeptidase, aspartate transaminase, platelets, and prothrombin time, was developed for diagnosing advanced fibrosis and cirrhosis in chronic liver disease. We aimed to evaluate the performance of eLIFT to predict liver fibrosis and cirrhosis in patients with chronic hepatitis B (CHB). Histologic and laboratory data of 747 CHB patients were analyzed. The performance of eLIFT for diagnosing liver fibrosis and cirrhosis was compared with that of aspartate transaminase to platelet ratio index (APRI) and fibrosis index based on the 4 factors (FIB-4). To predict advanced fibrosis, the AUROC of eLIFT was comparable with that of APRI (0.66 vs 0.71, p = 0.095) and FIB-4 (0.66 vs 0.67, p = 0.612). To predict severe fibrosis, the AUROC of eLIFT was lower than that of APRI (0.65 vs 0.83, p < 0.001) and FIB-4 (0.65 vs 0.82, p < 0.001). To predict cirrhosis, the AUROC of eLIFT was also lower than that of APRI (0.64 vs 0.85, p = 0.001) and FIB-4 (0.64 vs 0.76, p = 0.033). The eLIFT is not a good non-invasive test for the diagnosis of liver fibrosis and cirrhosis in CHB patients.
format	article
author	Qiang Li Chuan Lu Weixia Li Yuxian Huang Liang Chen
author_facet	Qiang Li Chuan Lu Weixia Li Yuxian Huang Liang Chen
author_sort	Qiang Li
title	Evaluation of eLIFT for Non-invasive Assessment of Liver fibrosis and Cirrhosis in Patients with Chronic Hepatitis B Virus Infection
title_short	Evaluation of eLIFT for Non-invasive Assessment of Liver fibrosis and Cirrhosis in Patients with Chronic Hepatitis B Virus Infection
title_full	Evaluation of eLIFT for Non-invasive Assessment of Liver fibrosis and Cirrhosis in Patients with Chronic Hepatitis B Virus Infection
title_fullStr	Evaluation of eLIFT for Non-invasive Assessment of Liver fibrosis and Cirrhosis in Patients with Chronic Hepatitis B Virus Infection
title_full_unstemmed	Evaluation of eLIFT for Non-invasive Assessment of Liver fibrosis and Cirrhosis in Patients with Chronic Hepatitis B Virus Infection
title_sort	evaluation of elift for non-invasive assessment of liver fibrosis and cirrhosis in patients with chronic hepatitis b virus infection
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/2b5c10b831b94534b2acdeed63ecce70
work_keys_str_mv	AT qiangli evaluationofeliftfornoninvasiveassessmentofliverfibrosisandcirrhosisinpatientswithchronichepatitisbvirusinfection AT chuanlu evaluationofeliftfornoninvasiveassessmentofliverfibrosisandcirrhosisinpatientswithchronichepatitisbvirusinfection AT weixiali evaluationofeliftfornoninvasiveassessmentofliverfibrosisandcirrhosisinpatientswithchronichepatitisbvirusinfection AT yuxianhuang evaluationofeliftfornoninvasiveassessmentofliverfibrosisandcirrhosisinpatientswithchronichepatitisbvirusinfection AT liangchen evaluationofeliftfornoninvasiveassessmentofliverfibrosisandcirrhosisinpatientswithchronichepatitisbvirusinfection
_version_	1718384892875636736

Evaluation of eLIFT for Non-invasive Assessment of Liver fibrosis and Cirrhosis in Patients with Chronic Hepatitis B Virus Infection

Ejemplares similares